Your browser doesn't support javascript.
loading
Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer.
Poel, Dennis; Rustenburg, François; Sie, Daoud; van Essen, Hendrik F; Eijk, Paul P; Bloemena, Elisabeth; Elhorst Benites, Teresita; van den Berg, Madeleine C; Vergeer, Marije R; Leemans, René C; Buffart, Tineke E; Ylstra, Bauke; Brakenhoff, Ruud H; Verheul, Henk M; Voortman, Jens.
Afiliação
  • Poel D; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, the Netherlands; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Rustenburg F; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurosurgery, Cancer Center Amsterdam, the Netherlands.
  • Sie D; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, the Netherlands.
  • van Essen HF; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, the Netherlands.
  • Eijk PP; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, the Netherlands.
  • Bloemena E; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, the Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Maxillofacial Surgery/Oral Pathology, Academic Center for Dentistry Amsterdam (ACTA), the Netherlands.
  • Elhorst Benites T; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, the Netherlands.
  • van den Berg MC; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, the Netherlands.
  • Vergeer MR; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiation Oncology, Cancer Center Amsterdam, the Netherlands.
  • Leemans RC; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam, the Netherlands.
  • Buffart TE; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, the Netherlands; Antoni van Leeuwenhoek Hospital, Department of Gastrointestinal Oncology, Amsterdam, the Netherlands.
  • Ylstra B; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, the Netherlands.
  • Brakenhoff RH; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam, the Netherlands.
  • Verheul HM; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, the Netherlands; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Voortman J; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, the Netherlands. Electronic address: j.voortman@amsterdamumc.nl.
Oral Oncol ; 109: 104851, 2020 Jun 22.
Article em En | MEDLINE | ID: mdl-32585557
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oral Oncol Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oral Oncol Ano de publicação: 2020 Tipo de documento: Article